Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 6/2017

27.10.2017 | Genetics of Heart Failure (K Adams, Section Editor)

Pharmacogenomics of the Natriuretic Peptide System in Heart Failure

verfasst von: Ahmed Abuzaanona, David Lanfear

Erschienen in: Current Heart Failure Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Heart failure (HF) continues to be a public health burden despite advances in therapy, and the natriuretic peptide (NP) system is clearly of critical importance in this setting, spawning valuable diagnostic and prognostic testing, such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), as well as current and future therapeutics, including recombinant natriuretic peptides (e.g., carperitide, nesiritide) and recently sacubitril, which inhibits the key clearance mechanism for NPs. This article intends to summarize the existing evidence for the role of NP system genetic variation on cardiovascular phenotypes relevant to HF with particular focus on the potential impact on pharmacologic therapies.

Recent Findings

Several genes in NP system have been interrogated, in many cases genetic variation impacting protein quantity and function or related disease states. Recent data supports genetic variants potentially impacting pharmacokinetics or dynamics of medications targeting the pathway.

Summary

Growing evidence indicates the importance of genetic variation to the functioning of the NP system and its pharmacologic manipulation.
Literatur
1.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.CrossRefPubMedPubMedCentral
2.
Ghani F, Wu A, Bijou R, et al. Circulating levels of B-type natriuretic peptide (BNP) are useful for diagnosis and are associated with severity of symptoms in chronic heart failure: preliminary data from a multicenter study with Bayer ADVIA Centaur (R) BNP assay. Clin Chem. 2003;49:A67–8.
3.
Tulevski II, Mulder BJ, van Veldhuisen DJ. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol. 2002;39:2080.CrossRefPubMed
4.
Adlbrecht C, Neuhold S, Hulsmann M et al. NT-proBNP as a means of triage for the risk of hospitalisation in primary care. Eur J Cardiovasc Prev Rehabil. 2011.
5.
Gale CP, White JE, Hunter A, et al. Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med (Hagerstown). 2011;12:613–8.CrossRef
6.
Feola M, Lombardo E, Taglieri C, Piccolo S, Vado A. Plasma BNP and renal failure as prognostic factors of mid-term clinical outcome in congestive heart failure patients. Int J Cardiol. 2011;149:114–5.CrossRefPubMed
7.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. Jama 2002;287:1531–1540.
8.
Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–53.CrossRefPubMed
9.
Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34:886–893c.CrossRefPubMed
10.
McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep. 2010;7:93–9.CrossRefPubMed
11.
Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8:e58287.CrossRefPubMedPubMedCentral
12.
Cannone V, Huntley BK, Olson TM, et al. Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension. 2013;
13.
Pereira NL, Lin D, Pelleymounter L, et al. Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation. Circ Cardiovasc Genet. 2013;6:201–10.CrossRefPubMedPubMedCentral
14.
Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, et al. The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc. 2011;86:210–8.CrossRefPubMedPubMedCentral
15.
Lanfear DE. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev. 2010;15:219–28.CrossRefPubMed
16.
Stoupakis G, Klapholz M. Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Heart Dis. 2003;5:215–23.CrossRefPubMed
17.
de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–22.CrossRefPubMed
18.
Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184–9.CrossRefPubMed
19.
Sabrane K, Kruse MN, Fabritz L, et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005;115:1666–74.CrossRefPubMedPubMedCentral
20.
Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44.CrossRefPubMed
21.
Lopez MJ, Wong SK, Kishimoto I, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase—a receptor for atrial natriuretic peptide. Nature. 1995;378:65–8.CrossRefPubMed
22.
Fujita T, Ito Y, Noda H, et al. Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man. J Clin Invest. 1987;80:832–40.CrossRefPubMedPubMedCentral
23.
D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004;101:113–29.CrossRefPubMed
24.
Kapoun AM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94:453–61.CrossRefPubMed
25.
Liang F, Kapoun AM, Lam A, et al. B-type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells. Endocrinology. 2007;148:3722–9.CrossRefPubMed
26.
Vellaichamy E, Kaur K, Pandey KN. Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides. 2007;28:893–9.CrossRefPubMed
27.
Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000;97:8525–9.CrossRefPubMedPubMedCentral
28.
Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78–81.CrossRefPubMed
29.
Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther. 2004;102:223–41.CrossRefPubMed
30.
Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet (London, England). 1993;341:1105–9.CrossRef
31.
Suga S, Nakao K, Itoh H, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of “vascular natriuretic peptide system”. J Clin Invest. 1992;90:1145–9.CrossRefPubMedPubMedCentral
32.
Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem. 2003;278:25847–52.CrossRefPubMed
33.
Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004–9.CrossRefPubMed
34.
Potter LR. Domain analysis of human transmembrane guanylyl cyclase receptors: implications for regulation. Front Biosci : J Virtual Library. 2005;10:1205–20.CrossRef
35.
Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature. 1989;341:68–72.CrossRefPubMed
36.
Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Phys. 1996;271:R373–80.
37.
Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (London, England : 1979). 2016;130:57–77.CrossRef
38.
Eiskjaer H, Bagger JP, Danielsen H, et al. Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man. Int J Cardiol. 1991;33:61–74.CrossRefPubMed
39.
Meirhaeghe A, Sandhu MS, McCarthy MI, et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet. 2007;16:1343–50.CrossRefPubMed
40.
Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natriuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther. 2007;21:55–62.CrossRefPubMed
41.
Takeishi Y, Toriyama S, Takabatake N, et al. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem Biophys Res Commun. 2007;362:480–4.CrossRefPubMed
42.
Musani SK, Fox ER, Kraja A, et al. Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study. Circ Cardiovasc Genet. 2015;8:122–30.CrossRefPubMedPubMedCentral
43.
Ellis KL, Newton-Cheh C, Wang TJ, et al. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol. 2011;50:695–701.CrossRefPubMed
44.
Johansson A, Eriksson N, Lindholm D, et al. Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet. 2016;25:1447–56.CrossRefPubMed
45.
Fox AA, Collard CD, Shernan SK, et al. Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology. 2009;110:738–47.CrossRefPubMedPubMedCentral
46.
Choquet H, Cavalcanti-Proenca C, Lecoeur C, et al. The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects. Hum Mol Genet. 2009;18:2495–501.CrossRefPubMed
47.
Pfister R, Sharp S, Luben R, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8:e1001112.CrossRefPubMedPubMedCentral
48.
Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348–53.CrossRefPubMedPubMedCentral
49.
Ono K, Mannami T, Baba S, Tomoike H, Suga S, Iwai N. A single-nucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens Res : Off J Jpn Soc Hypertens. 2002;25:727–30.CrossRef
50.
Yan W, Sheng N, Seto M, Morser J, Wu Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem. 1999;274:14926–35.CrossRefPubMed
51.
Wu F, Yan W, Pan J, Morser J, Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem. 2002;277:16900–5.CrossRefPubMed
52.
53.
Peleg A, Ghanim D, Vered S, Hasin Y. Serum corin is reduced and predicts adverse outcome in non-ST-elevation acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2013;2:159–65.CrossRefPubMedPubMedCentral
54.
Dries DL, Victor RG, Rame JE, et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation. 2005;112:2403–10.CrossRefPubMed
55.
Rame JE, Drazner MH, Post W, et al. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. Hypertension (Dallas, Tex: 1979). 2007;49:857–64.CrossRef
56.
Rame JE, Tam SW, McNamara D, et al. Dysfunctional corin i555 (p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail. 2009;2:541–8.CrossRefPubMedPubMedCentral
57.
Wang W, Liao X, Fukuda K, et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res. 2008;103:502–8.CrossRefPubMedPubMedCentral
58.
Wang W, Cui Y, Shen J, et al. Salt-sensitive hypertension and cardiac hypertrophy in transgenic mice expressing a corin variant identified in blacks. Hypertension. 2012;60:1352–8.CrossRefPubMedPubMedCentral
59.
Dong N, Fang C, Jiang Y, et al. Corin mutation R539C from hypertensive patients impairs zymogen activation and generates an inactive alternative ectodomain fragment. J Biol Chem. 2013;288:7867–74.CrossRefPubMedPubMedCentral
60.
61.
Ganesh SK, Tragante V, Guo W, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet. 2013;22:1663–78.CrossRefPubMedPubMedCentral
62.
Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9.CrossRefPubMed
63.
Sun Q-X, Zhou H-M, Du Q-W. Association of Rs2071410 on furin with transient ischemic attack susceptibility and prognosis in a Chinese population. Med Sci Monit : Int Med J Exp Clin Res. 2016;22:3828–34.CrossRef
64.
Turpeinen H, Raitoharju E, Oksanen A, et al. Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL. Atherosclerosis. 2011;219:799–806.CrossRefPubMed
65.
Knowles JW, Erickson LM, Guy VK, Sigel CS, Wilder JC, Maeda N. Common variations in noncoding regions of the human natriuretic peptide receptor a gene have quantitative effects. Hum Genet. 2003;112:62–70.CrossRefPubMed
66.
Pitzalis MV, Sarzani R, Dessi-Fulgheri P, et al. Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J Hypertens. 2003;21:1491–6.CrossRefPubMed
67.
Rubattu S, Stanzione R, Di Angelantonio E, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke. 2004;35:814–8.CrossRefPubMed
68.
Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K. Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res. 2000;86:841–5.CrossRefPubMed
69.
Nakayama T, Soma M, Mizutani Y, et al. A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: possible association with essential hypertension. Hypertens Res. 2002;25:395–401.CrossRefPubMed
70.
Rubattu S, Bigatti G, Evangelista A, et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2006;48:499–505.CrossRefPubMed
71.
Lanfear DE, Sunkara B, Li J, et al. Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res. 2013;6:826–33.CrossRefPubMedPubMedCentral
72.
• Lanfear DE, Li J, Abbas R, et al. Genetic factors influencing B-type natriuretic peptide-mediated production of cyclic guanosine monophosphate and blood pressure effects in heart failure patients. J Cardiovasc Transl Res. 2015;8:545–53. This study demonstrated that genetic variation in MME and NPR was associated with the pharmacokinetics of BNP in humans with heart failure. CrossRefPubMedPubMedCentral
73.
Rehemudula D, Nakayama T, Soma M, et al. Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Circ Res. 1999;84:605–10.CrossRefPubMed
74.
Matsukawa N, Grzesik WJ, Takahashi N, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A. 1999;96:7403–8.CrossRefPubMedPubMedCentral
75.
Saulnier PJ, Roussel R, Halimi JM, et al. Impact of natriuretic peptide clearance receptor (NPR3) gene variants on blood pressure in type 2 diabetes. Diabetes Care. 2011;34:1199–204.CrossRefPubMedPubMedCentral
76.
Kato N, Takeuchi F, Tabara Y, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011;43:531–8.CrossRefPubMedPubMedCentral
77.
Zhu X, Young J, Fox E, et al. Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet. 2011;20:2285–95.CrossRefPubMedPubMedCentral
78.
Fox AA, Nascimben L, Body SC, et al. Increased perioperative B-type natriuretic peptide associates with heart failure hospitalization or heart failure death after coronary artery bypass graft surgery. Anesthesiology. 2013;119
79.
Hu Q, Liu Q, Wang S, et al. NPR-C gene polymorphism is associated with increased susceptibility to coronary artery disease in Chinese Han population: a multicenter study. Oncotarget. 2016;7:33662–74.CrossRefPubMedPubMedCentral
80.
Lanfear DE, Stolker J, Marsh S, Rich MW, McLeod HL. Natriuretic peptide receptor 3 (NPR3) genotype modulates the relationship between B-type natriuretic peptide (BNP) and left ventricular end-diastolic pressure. Therapy. 2006;3:765–71.CrossRef
81.
• Lanfear DE, Chow S, Padhukasahasram B, et al. Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail. 2014;20:662–8. This study demonstrated that genetic variation in MME was associated with alterations in cGMP production and blood pressure change in response to BNP infusion in humans with heart failure. CrossRefPubMedPubMedCentral
82.
Pereira NL, Aksoy P, Moon I, et al. Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol. 2010;49:864–74.CrossRefPubMedPubMedCentral
Metadaten
Titel
Pharmacogenomics of the Natriuretic Peptide System in Heart Failure
verfasst von
Ahmed Abuzaanona
David Lanfear
Publikationsdatum
27.10.2017
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 6/2017
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-017-0365-5

Weitere Artikel der Ausgabe 6/2017

Current Heart Failure Reports 6/2017 Zur Ausgabe

Genetics of Heart Failure (K Adams, Section Editor)

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure

Genetics of Heart Failure (K Adams, Section Editor)

Clinical Application of Genetic Testing in Heart Failure

Prevention of Heart Failure (M. St. John Sutton, Section Editor)

Pulmonary Hypertension Due to Left Ventricular Cardiomyopathy: Is it the Result or Cause of Disease Progression?

Comorbidities of Heart Failure (C Angermann and F Edelmann, Section Editors)

Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus

Prevention of Heart Failure (M Sutton, Section Editor)

Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

24.04.2024 | Adipositas | Nachrichten

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 | ACC 2024 | Nachrichten

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen